Why Isolated Systolic Hypertension Develops in the Elderly
Loss of the Windkessel Effect
Arterial Stiffness → Isolated Systolic Hypertension
- Normal aorta (Windkessel effect): expands during systole to absorb stroke volume → damped pressure wave; recoils during diastole to maintain diastolic pressure and coronary perfusion
- Aging aorta (stiff): elastin fragments and replaced by collagen; AGE cross-linking; medial calcification; endothelial dysfunction reduces nitric oxide
- Result — isolated systolic hypertension: SBP rises (no damping) + DBP falls (no elastic recoil) = widened pulse pressure
- Pulse pressure above 60–70 mm Hg predicts high cardiovascular event rates
- Systolic BP more powerful cardiovascular predictor than diastolic after age 50–55
- J-curve caution: avoid reducing DBP below 65–70 mm Hg in patients with established coronary artery disease — coronary perfusion is diastole-dependent
Trial Evidence — Treatment Benefit Is Firmly Established
Low-Renin ISH Responds Best to Diuretics and CCBs
- SHEP (1991): chlorthalidone in ISH (age ≥60) vs placebo → 36% reduction in stroke; 54% reduction in heart failure; established thiazide-like diuretics as cornerstone agents
- Syst-Eur (1997): nitrendipine (DHP CCB) in ISH (age ≥60) vs placebo → 42% reduction in stroke; 31% reduction in cardiovascular events; established DHP CCBs as equally effective first-line agents
- HYVET (2008): indapamide ± perindopril in age ≥80 vs placebo → 21% reduction in all-cause mortality; 64% reduction in heart failure; fewer serious adverse events than placebo — proven safe in very elderly
- SPRINT elderly subgroup (2016): intensive target below 120 mm Hg (by automated unattended measurement ≈130 mm Hg standard) in age ≥75 → 34% reduction in cardiovascular events; 33% reduction in mortality in non-frail elderly
Drug Selection in Elderly Hypertension — Preferred vs Avoid
First-Line — Effective in Low-Renin ISH
Preferred Agents
- Thiazide-like diuretics (chlorthalidone, indapamide): SHEP and HYVET evidence; most effective in volume-dependent ISH; chlorthalidone 12.5–25 mg or indapamide 1.25–2.5 mg; monitor sodium (hyponatremia risk especially in elderly women), potassium, creatinine; check orthostatic BP every visit
- DHP CCBs (amlodipine): Syst-Eur evidence; renin-independent mechanism — effective in low-renin ISH; amlodipine preferred (half-life 35–50 hours, smooth 24-hour control, buffer for missed doses); no electrolyte or renal effects; peripheral edema managed by adding RAAS inhibitor
- ACEi or ARB (with compelling indication): less effective as monotherapy in low-renin ISH; effective add-on to diuretic or CCB; ARB preferred over ACEi (avoid cough in elderly); perindopril added to indapamide in HYVET; monitor creatinine and potassium closely
- Cognitively neutral and orthostatic-safe: amlodipine, chlorthalidone, ARBs — preferred when cognitive effects or falls are concerns
Use with Caution or Avoid in Elderly ISH
Problematic Agents
- Beta-blockers: not first-line for isolated systolic hypertension; less effective for systolic reduction; fatigue, exercise intolerance, falls, depression, cold extremities; reserve for compelling indications (HFrEF, post-MI, AF rate control); prefer bisoprolol or nebivolol; avoid atenolol (renal accumulation, LIFE trial inferior outcomes)
- Alpha-1 blockers (doxazosin, terazosin): high orthostatic hypotension and first-dose syncope risk → falls and hip fractures; ALLHAT: increased heart failure as monotherapy; useful only as add-on for concurrent BPH — lowest dose at bedtime
- Centrally acting agents (clonidine, methyldopa): sedation, cognitive impairment, depression, falls — generally avoided in the elderly; use only when all other options have failed
- Short-acting DHP CCBs (immediate-release nifedipine): contraindicated for hypertension management in elderly — exaggerated reflex tachycardia and BP variability, harmful in concurrent CAD
Frailty-Adjusted Targets & Start-Low-Go-Slow Dosing
Frailty Modifies the Benefit-Risk Calculation — Individualize Aggressively
Targets and Approach by Frailty Status
| Frailty Status (Clinical Frailty Scale) |
Systolic Target |
Clinical Approach |
| Fit (CFS 1–3) | Below 130 mm Hg | Treat to evidence-based targets; SPRINT-level targets reasonable in non-frail elderly aged 75 or above; standard monitoring |
| Pre-frail (CFS 4–5) | Below 140 mm Hg | Standard targets with careful monitoring; check orthostatic BP every visit; titrate every 4–6 weeks rather than 2–4 weeks |
| Frail (CFS 6–8) | Individualized — quality of life priority | De-prescribing should be actively considered if adverse effects (falls, orthostatic hypotension, declining function) are present; benefit-risk shifts unfavorably with advancing frailty |
| Very frail / End of life (CFS 8–9) | Withdraw if not tolerated | Antihypertensive withdrawal should be actively considered; comfort and quality of life take priority over blood pressure targets |
Start-Low-Go-Slow — Standard Starting Doses in Elderly Patients
Begin at half the standard adult starting dose: Chlorthalidone 6.25 mg (standard 12.5 mg) • Amlodipine 2.5 mg (standard 5 mg) • Perindopril 2 mg (standard 4 mg) • Losartan 25 mg (standard 50 mg) • Lisinopril 2.5 mg (standard 5 mg). Titrate every 4–6 weeks (not 2–4). Review the complete medication list at every visit — average elderly hypertensive patient takes 5–7 prescriptions; NSAIDs blunt diuretics and RAAS inhibitors and must be identified every review.
Orthostatic Hypotension & Age-Related Pharmacokinetic Changes
Prevalence 20% Community / 50% Institutionalized
Orthostatic Hypotension
- Definition: SBP fall ≥20 mm Hg or DBP fall ≥10 mm Hg within 3 minutes of standing
- Associated with approximately 2× risk of falls, syncope, and cardiovascular events
- Most problematic agents: alpha-1 blockers, loop diuretics, CCBs
- Check BP sitting AND standing at every visit in elderly hypertensive patients
- Management: simplify regimen; avoid diuretics in evening; adequate hydration; compression stockings; slow positional changes; avoid alcohol
GFR Declines ~1 mL/min/Year After Age 40
Pharmacokinetic Changes with Aging
- Use CKD-EPI equation (not serum creatinine alone) — reduced muscle mass causes creatinine to underestimate renal impairment
- Renally excreted drugs accumulate: atenolol, lisinopril (dose reduction required)
- Reduced hepatic first-pass: higher bioavailability of labetalol, metoprolol, nifedipine, amlodipine
- Increased body fat relative to lean mass: lipophilic drugs have larger volume of distribution and longer half-lives
- Lipophilic drugs cross blood-brain barrier more readily: increased CNS sensitivity to clonidine, methyldopa, lipophilic beta-blockers
- Polypharmacy risk: 5–7 concurrent medications average; NSAIDs are the most common BP-raising interactant